Glucose-dependent insulinotropic polypeptide (GIP) is one of two enteroinsular hormones, playing a crucial role in linking nutrient intake with whole-body metabolism.

FCN-159 is an orally effective selective MEK1/2 inhibitor and a prospective targeted therapy drug for tumors mutated by BRAF or RAS.

This article will highlight the latest list of cancer pipeline drugs, specifically focussed on breast cancer pipeline drugs, pharmaceutical companies of researching breast cancer drugs, drug target of breast cancer, drug type of breast cancer and countries/locations of researching breast cancer drugs.

Zenocutuzumab is a bispecific antibody targeting HER2/HER3 developed by Merus NV. On July 7, 2023, the U.S. FDA granted Zenocutuzumab breakthrough therapy desig-nation for NRG1 fusion-positive non-small cell lung cancer.

JAK3 is a narrow-spectrum member that only regulates γc cytokines, thus becoming an ideal potential target.

Selinexor, a small molecule drug targeting XPO1, is developed by Karyopharm Therapeutics, Inc.

The recent launch of the Clinical Trial Result Database on the Synapse Database resolves the problems of data comprehensiveness and selection.

Lanifibranor, a small-molecule drug targeting PPARα + PPARγ + PPARδ, was initially developed by AbbVie, Inc.

This study first revealed that dexmedetomidine inhibits the microglial synaptic elimination process mediated by the complement C3-C3aR signaling pathway.

Brogidirsen is a drug targeting DMD exon 44 antisense oligonucleotide, developed by Nippon Shinyaku Co.

Synapse functions as an indispensable free drug pipeline database tool for pharmaceutical and biotech sectors, enhancing drug pipelines and marketed drugs by presenting analytical intelligence on a wide range of drug discovery and development.

Fruquintinib is a small molecule drug targeting VEGFR1, VEGFR2, and VEGFR3. This drug was initially developed by Hutchison Whampoa Medicine (Shanghai) Co., Ltd.